Abstract A134: Therapeutic targeting of Hdm2/HdmX E3 ligase with bioactive cyclotides
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a134
Abstract: Reactivation of tumor-suppressor p53 for targeted cancer therapy is an attractive strategy for cancers bearing wild-type (WT) p53. Targeting the Hdm2-p53 interface or HdmX-p53 interface or both has been a focus in the field. However,… read more here.
Keywords: hdmx; hdm2 hdmx; p53; bioactive cyclotides ... See more keywords